Pharmacy in Clinical Trials
On this page
Direct answer
Pharmacy in clinical trials means custody of the investigational product (IP) and the systems that keep a trial blind, temperature-compliant and accountable, under ICH-GCP (E6; R3 adopted January 2025) and India's New Drugs and Clinical Trials Rules, 2019, which replaced Schedule Y. The phase ladder frames everything: Phase 0 microdosing in about 10-15 subjects, Phase I 20-100 healthy volunteers for pharmacokinetics and maximum tolerated dose, Phase II 100-300 patients for dose-finding, Phase III 1,000-5,000 patients for confirmatory evidence, Phase IV post-marketing surveillance. The trial pharmacist receives and quarantines IP, verifies temperature records, stores per protocol (commonly 2-8 or 15-25 degrees Celsius), dispenses against randomisation numbers, maintains accountability logs reconciling received, dispensed, returned and destroyed units, controls emergency code-break procedures and prepares documentation for monitoring and audits. Indian compliance anchors: CTRI registration before enrolment, CDSCO-registered ethics committees of at least seven members, informed consent with audio-visual recording for vulnerable subjects, and SAE reporting to the licensing authority within 24 hours with the detailed report in 14 days.
What you must remember
- Phase sizes: 0 (microdose, ~10-15), I (20-100 healthy), II (100-300 patients), III (1,000-5,000), IV (post-marketing) — the single most-quoted ladder in the chapter.
- Indian legal shift: NDCT Rules 2019 superseded Schedule Y — old question banks remain the trap; the Rules added injury compensation norms and streamlined approvals.
- GCP identity: ICH E6(R3), adopted January 2025, restructured into principles plus annexes with risk-based quality management; the earlier E6(R2) remains the familiar reference version.
- SAE clock: report to the licensing authority and ethics committee within 24 hours, detailed report within 14 days per the 2019 Rules — a number examiners test precisely.
- CTRI: prospective registration of the trial on the Clinical Trials Registry-India before first patient enrolment is mandatory for Indian sites.
- Ethics committee: minimum seven members, CDSCO-registered, with competence covering non-scientific and lay perspectives; it approves protocol, consent documents and amendments.
- IP management chain: receipt and quarantine, temperature-excursion documentation, blinded dispensing, accountability logs (received/dispensed/returned/destroyed), expiry and retest dating, final reconciliation and witnessed destruction.
- Consent essentials: freely given, documented, in the participant's language; audio-visual recording where subjects are vulnerable, per Indian rules.
A day as the trial-site pharmacist
The courier arrives with a consignment of IP. The temperature data logger is read before it enters the pharmacy; an excursion outside 2-8 degrees sends the consignment into quarantine pending the sponsor's assessment — nothing dispensed from a broken cold chain. Receipt is logged: quantity, batch, expiry, code block. Storage follows the protocol, with IP physically separate from commercial stock. At the afternoon visit, consent is verified, identity matched to the randomisation number, the kit dispensed against the accountability log, and compliance counselling given, pill counts from the previous period reconciled first. Every movement has a line in the log that a monitor will later source-verify.
The harder scenarios test systems. A participant hospitalised elsewhere with a serious adverse event: the pharmacist supports the investigator's 24-hour notification with pharmacy records. A participant spills half her supply: the deviation is documented and replacement issued per sponsor instructions. And the rarest event — a blinded emergency where the physician must know what the patient received — follows the code-break procedure, documented afterwards and notified to the sponsor. At closeout, returned drugs are reconciled and destroyed under witness, the final accountability document signed by pharmacist and monitor together. That paper trail is the trial's integrity made visible.
Where students slip
Two regulatory eras are mixed: quoting Schedule Y as current law is quoting the pre-2019 regime, and examiners reward the supersession. Second, the SAE timeline is exact — 24-hour initial, 14-day detailed — and "prompt reporting" forfeits the numbers. Third, phases are labelled by purpose alone; add subject numbers, because MCQs test sizes. Fourth, the emergency code-break is a documented procedure with a paper trail, not a casual enquiry to the sponsor. Finally, blinding logistics — identical packaging, matching placebos, shelf-life management — are the pharmacy-specific content that separates pharmacists from GCP-generalists.
Frequently asked questions
What are the phases of clinical trials and their typical sizes?
Phase 0 microdosing (~10-15 subjects), Phase I 20-100 healthy volunteers, Phase II 100-300 patients, Phase III 1,000-5,000 patients, and Phase IV post-marketing surveillance in real-world populations.
Which rules currently govern clinical trials in India?
The New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, which replaced Schedule Y; trials must also be registered prospectively on CTRI.
What is the reporting timeline for a serious adverse event in India?
Initial notification to the licensing authority and ethics committee within 24 hours, followed by the detailed report within 14 days, per the NDCT Rules 2019.
What does investigational product accountability involve?
Documented tracking of every unit from receipt and quarantine through dispensing, returns and witnessed destruction, reconciled at monitoring visits — the core trial-pharmacy responsibility.
How is emergency unblinding handled at a site?
Through a pre-defined code-break procedure with documented justification and immediate sponsor notification; the pharmacist safeguards the codes and records the event, preserving trial integrity.